# Regeneron Pharmaceuticals, Inc. (REGN) — Q1-2018 Earnings Results

**Report date:** 2018-05-03 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q1-2018

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Down 1.26%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.70 | N/A | +0.42% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Management expressed satisfaction with the EPS results, indicating a strong performance. However, they did not provide specific guidance for future revenue.

**Key quotes:**

> We are pleased with our EPS performance this quarter.

> While we did not provide revenue guidance, we remain focused on our pipeline.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's earnings report showed a positive surprise in EPS, which reflects the company's profitability. However, the stock fell by 1.26%, likely due to the absence of revenue guidance and uncertainty about future performance. Investors may be cautious as they await more details on revenue expectations.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q1-2018_